TroFuse-019, NCT06312137: A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) |
|
|
| Recruiting | 3 | 780 | Europe, Canada, US, RoW | Sacituzumab tirumotecan, MK-2870, Pembrolizumab, MK-3475, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel | Merck Sharp & Dohme LLC | Non Small Cell Lung Cancer | 02/34 | 10/34 | | |
